Return to: Pediatrics : Medical School : Academic Health Center : myU : U of M Home
Gold University of Minnesota M. Skip to main content. Link to University of Minnesota homepage
One Stop | Directories | Search U of M 
Division of Endocrinology, Department of Pediatrics
Whats Inside
For Patients and Families

Faculty Research

Education

Faculty and Staff

Research Patient Opportunities

Contact Us

For Healthcare Providers

 

Peds Endocrinology Home


University Pediatrics Foundation - Make a Gift

Viking Children's Fund

Children's Cancer Research Fund

Department of Pediatrics > Endocrinology > Research Patient Opportunities > CTLA 4 (Abatacept) New Onset Study

Printer-friendly version   Mail this page to a friend

CTLA 4 (Abatacept) New Onset Study


The purpose of this study is to prevent the progression of type 1 diabetes in those with new onset type 1 diabetes. Age is 6-45. Patients are randomly assigned to receive infusions of CTLA 4, (which is used in other autoimmune diseases) or a placebo. There is no cost for study participation.

Contact Person: Mary Ann Boes, RNC, CDE
Phone: 612-625-9709
Toll Free: 800-688-5252 ext. 59709
Email: boesx003@umn.edu

Feedback | Notice of Privacy Practices


 
©2002-2008 Regents of the University of Minnesota. All rights reserved. Trouble seeing the text? | Contact U of M | Privacy
The University of Minnesota is an equal opportunity educator and employer.
  Last modified on Monday Jun 02, 2008